Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which studied lenvatinib in radioiodine-refractory differentiated thyroid cancer.
Josh Kremer, MD
Advertisement
Articles by Josh Kremer, MD
Advertisement
Latest Updated Articles
Lenvatinib Delays Thyroid Cancer ProgressionPublished: July 4th 2014 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC
2
Trastuzumab Deruxtecan Regimen Accepted for Review in HER2+ Breast Cancer
3
Uncovering Subsequent Research Considerations for Tarlatamab in ES-SCLC
4
FDA Grants Fast Track Designation to Novel PIK3α Inhibitor in Breast Cancer
5
